Biotech company Biogen (NASDAQ:BIIB) will be announcing earnings results tomorrow before the bell. Here’s what you need to ...

Let's look at five pharma and drug companies, PFE, LLY, AMGN, BIIB and REGN, which are scheduled to release their ...

With a market cap of $17.4 billion, Biogen Inc. (BIIB) is a global biotechnology leader focused on discovering, developing, ...

Biogen’s lack of insider buying and reduced R&D spending raise concerns, but its future growth prospects remain. Find out why ...

Biogen Inc. closed 49.79% below its 52-week high of $238.00, which the company achieved on July 12th.

Biogen Inc. closed 51.05% below its 52-week high of $238.00, which the company reached on July 12th.

Analysts fell to the sidelines weighing in on Biogen (BIIB – Research Report) and Sanofi (SNY – Research Report) with neutral ratings, ...

Jefferies analyst Michael Yee maintained a Hold rating on Biogen (BIIB – Research Report) today and set a price target of $130.00. The ...

Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks ...

Investors in Biogen Inc (Symbol: BIIB) saw new options become available today, for the May 23rd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BIIB options ...

In trading on Friday, shares of Biogen Inc (Symbol: BIIB) entered into oversold territory, hitting an RSI reading of 27.8, after changing hands as low as $123.02 per share. By comparison ...